{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:03:08Z","timestamp":1700582588278},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T00:00:00Z","timestamp":1253750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study compared the effectiveness of rosuvastatin (RSV) to other statins prescribed in clinical practice in prevention of cardiovascular (CV) events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This longitudinal inception cohort study, using Thomson Healthcare's MarketScan databases, included patients aged\u2009\u2265\u200918 starting statin therapy during August 2003\u2013December 2005. Patients were followed until 90 days after index statin monotherapy exposure, start of another lipid\u2010lowering therapy, an event, end of eligibility, or end of study. The primary endpoint was a composite of CV death (in\u2010hospital only), myocardial infarction, unstable angina, coronary revascularization, stroke, and carotid revascularization. Adjusted time\u2010to\u2010event analyses incorporating a propensity score covariate were used, and analyses were stratified by duration of statin exposure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 395\u2009039 patients who met inclusion\/exclusion criteria, 12% initiated RSV, and 9622 (2.4%) of the total patient population experienced an outcome event. The median duration of statin treatment and follow\u2010up was 100 days and 180 days, respectively. No statistically significant difference in CV event rates between RSV and other statins was observed after adjustment for demographics and medical\/prescription history (HR\u2009=\u20090.99, 95%CI\u2009=\u20090.93\u20131.06). However, with longer exposure time, there was a suggestion of increased benefit with RSV compared to other statins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The primary analysis showed similar incidence rates of CV\u2010related events between the statin cohorts over a median of 180 days of follow\u2010up. Copyright \u00a9 2009 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1843","type":"journal-article","created":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T07:54:10Z","timestamp":1253778850000},"page":"1214-1222","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events\u2014a cohort study in 395\u2009039 patients from clinical practice"],"prefix":"10.1002","volume":"18","author":[{"given":"Stephen P.","family":"Motsko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Russmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen E.","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varinder P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby M.","family":"Vendiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9,24]]},"reference":[{"issue":"344","key":"e_1_2_1_2_2","first-page":"1383","article-title":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"19","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391902"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.08.057"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A308"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.19.2437"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.9.1071"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00965-X"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00530-7"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.2146\/060104"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.4.469"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X182167"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X219580"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.01.003"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X61866"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1041403"},{"key":"e_1_2_1_24_2","unstructured":"WillkeRJ ZhouS VogelRA LePetriB.Differences in real\u2010world cardiovascular event rates between leading atorvastatin and simvastatin among new users when LDL\u2010lowering is controlled.47th Symposium on CV Epidemiology and Prevention (AHA). 28 February2007."},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00163.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl391"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1711"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.82.2.243"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780142404"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.02.013"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1999.10198.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000032240.28636.BD"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X182167"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"e_1_2_1_36_2","first-page":"280","article-title":"Switching statins: the impact on patient outcomes","volume":"14","author":"Phillips B","year":"2007","journal-title":"British J Cardiol"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1843","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T01:39:13Z","timestamp":1700012353000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,24]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1002\/pds.1843"],"URL":"https:\/\/doi.org\/10.1002\/pds.1843","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,24]]}}}